Loading
DIAMOND, a UK trial run from Barts in London, asks whether adding the immunotherapy durvalumab to the antibody-drug conjugate datopotamab deruxtecan helps women with PD-L1-negative metastatic triple-negative breast cancer, the group immunotherapy alone does not help. It opened in October 2025 and is recruiting 140 patients.
DIAMOND (NCT06954480; also on the ISRCTN registry) is an open-label randomised phase 2 trial sponsored by Queen Mary University of London with AstraZeneca, randomising 140 patients with PD-L1-negative metastatic triple-negative breast cancer to datopotamab deruxtecan with durvalumab or datopotamab deruxtecan alone; the primary endpoint is progression-free survival by RECIST 1.1. It started on 27 October 2025 with primary completion expected in February 2028. Its rationale is the BEGONIA arm 7 result (confirmed response 79 percent with the combination regardless of PD-L1) against the TROPION-Breast02 result for the conjugate alone in a 90 percent PD-L1-negative population, and it is the only randomised test of an ADC plus checkpoint inhibitor restricted to PD-L1-negative disease. Sites: Barts Cancer Institute Centre of Experimental Cancer Medicine and Barts Health NHS Trust, London.
Shares Datopotamab deruxtecan, Durvalumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites).
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic triple-negative breast cancer, AstraZeneca.
Shares TROPION-Breast05, TROPION-Breast02, TROP2, Datopotamab deruxtecan.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC).
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic triple-negative breast cancer, Antibody-drug conjugate (ADC).
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Durvalumab, AstraZeneca.
Shares Sacituzumab govitecan, Durvalumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites).